NasdaqCM - Nasdaq Real Time Price USD

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

0.8197

+0.0022

+(0.27%)

At close: May 9 at 4:00:00 PM EDT

0.8035

-0.02

(-1.98%)

After hours: May 9 at 7:00:12 PM EDT

Reviva to Participate in the Citizens Life Sciences Conference

CUPERTINO, Calif., April 29, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Citizens Life Sciences Conference, taking place May 7-8, 2025, in New Yo

GlobeNewswire 12 days ago

RVPH
+0.27%

RVPHW
Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

CUPERTINO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present a late-breaking poster presentation on the RECOVER 12-month open label extensio

GlobeNewswire 17 days ago

RVPH
+0.27%

RVPHW
RVPH: M&A Deals Highlight Brilaroxazine Value

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Materially Undervalued Over the past 18 months, several multi-billion-dollar M&A transactions have targeted assets treating schizophrenia. At the time these deals were announced, only one asset had received FDA approval, while the two others remained under review. Notable transactions include Bristol-Myers Squibb's $14

Zacks Small Cap Research last month

RVPHW
Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

– Favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year for once daily brilaroxazine in open-label extension (OLE) trial – – Registrational Phase 3 RECOVER-2 trial initiation for brilaroxazine expected mid-2025 – – Full data set from RECOVER OLE expected in Q2 2025 – CUPERTINO, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek

GlobeNewswire last month

RVPH
+0.27%

RVPHW
Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

CUPERTINO, Calif., March 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, announced today topline data from the long-term open label extension portion of the Phase 3 RECOVER study evaluating brilaroxazine in schizophrenia will be presented as part of an oral presentation at the

GlobeNewswire last month

RVPH
+0.27%

RVPHW
Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

CUPERTINO, Calif., Feb. 04, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference, taking place

GlobeNewswire 3 months ago

RVPH
+0.27%

RVPHW
Reviva to Participate in the 2025 BIO CEO & Investor Conference

CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 2025 BIO CEO & Investor Conference, taking plac

GlobeNewswire 3 months ago

RVPH
+0.27%

RVPHW
Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

CUPERTINO, Calif., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a webcasted presentation at the Lytham Partners 2025 Investor Healthcare

GlobeNewswire 4 months ago

RVPH
+0.27%

RVPHW
RVPH: Preliminary OLE Readout

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Open Label Extension Initial Readout Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported preliminary results from its open label extension (OLE) portion of the Phase III RECOVER trial. Brilaroxazine showed a favorable long-term safety profile and improving efficacy over the one-year observation period. The

Zacks Small Cap Research 4 months ago

RVPHW
Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer Announces Business Updates NEW YORK, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a biopharmaceutical company dedicated to creating transformative treatments for rare disease, today announced the following leadership changes, effective immediately: John H. Johnson, a recognized leader in the pharmaceutical and biotechnology industry, has been named Executive Chairman;Dr

GlobeNewswire 4 months ago

RVPH
+0.27%

RVPHW

VSTM
Reviva Pharmaceuticals Strengthens Financial Position with Offering

An update from Reviva Pharmaceuticals Holdings ( (RVPH) ) is now available. Reviva Pharmaceuticals announced an underwriting agreement with Citizens JMP Securities for a public offering, raising $18 million through the sale of common stock and warrants. The net proceeds are intended for research and development, working capital, and general corporate purposes. This move aims to strengthen Reviva’s financial position and support its drug development activities. More about Reviva Pharmaceuticals H

TipRanks 4 months ago

RVPH
+0.27%

RVPHW
Top Midday Decliners

Vaccinex (VCNX) shares will be delisted from the Nasdaq stock exchange on Wednesday after the compan

PREMIUM
MT Newswires 4 months ago

VCNX

RVPHW
Reviva Announces Proposed Public Offering

CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that it is proposing to offer and sell, subject to market conditions, shares of its common stock (or common share equivalents in lieu thereof) and warrants to pur

GlobeNewswire 4 months ago

RVPH
+0.27%

RVPHW
Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

– Once daily brilaroxazine demonstrated favorable long-term safety and robust broad-spectrum efficacy sustained over 1-year – – Generally well-tolerated with low rates of adverse events and discontinuation – – Full data set from open-label extension (OLE) of RECOVER expected in Q1 2025 – CUPERTINO, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to addres

GlobeNewswire 4 months ago

RVPH
+0.27%

RVPHW
RVPH: Year-End OLE Update

By John Vandermosten, CFA NASDAQ:RVPH READ THE FULL RVPH RESEARCH REPORT Operational and Financial Results On November 14 th , 2024, Reviva Pharmaceutical Holdings, Inc. (NASDAQ:RVPH) reported third quarter 2024 financial and operational results and filed its Form 10-Q with the SEC. Reviva provided updates on its open label extension (OLE) trial and provided guidance for further milestones for

Zacks Small Cap Research 5 months ago

RVPHW

ABBV
Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

– 108 patients have completed 1-year of treatment in 1-year open-label extension (OLE) trial – – Vocal biomarker speech latency data from RECOVER trial reinforce brilaroxazine’s improvement on negative symptoms and other key symptom domains of schizophrenia – – Topline data from OLE trial expected in December 2024 – CUPERTINO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing

GlobeNewswire 5 months ago

RVPH
+0.27%

RVPHW
Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

– 108 patients have completed 1-year of treatment – – Brilaroxazine is generally well tolerated to date in patients with acute and stable schizophrenia – – Topline data from 1-year open-label extension (OLE) trial now expected in December 2024 – CUPERTINO, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of centr

GlobeNewswire 5 months ago

RVPH
+0.27%

RVPHW
Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

CUPERTINO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that positive speech latency data for brilaroxazine in schizophrenia from the Phase 3 RECOVER trial will be presented as a poster presentation at the CNS Summit 2

GlobeNewswire 6 months ago

RVPH
+0.27%

RVPHW
Reviva to Participate in the UBS Global Healthcare Conference

CUPERTINO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the UBS Global Healthcare Conference, taking place Nov

GlobeNewswire 6 months ago

RVPH
+0.27%

RVPHW
Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

CUPERTINO, Calif., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a fireside chat at the 2024 Maxim Healthcare Virtual Summit, taking place

GlobeNewswire 6 months ago

RVPH
+0.27%

RVPHW

Performance Overview

Return	RVPH	S&P 500 (^GSPC)
YTD	-54.71%	-3.77%
1-Year	-61.70%	+8.55%
3-Year	-52.34%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Reviva Pharmaceuticals Holdings, Inc. (RVPH)

Reviva to Participate in the Citizens Life Sciences Conference

Reviva to Present Late-Breaking Poster on the RECOVER Long-term Open Label Extension Trial for Brilaroxazine in Schizophrenia at the 2025 ASCP Annual Meeting

RVPH: M&A Deals Highlight Brilaroxazine Value

Reviva Reports Full Year 2024 Financial Results and Recent Business Highlights

Reviva to Present Brilaroxazine Topline Data for Long-Term OLE Portion of RECOVER Study in Schizophrenia at 2025 SIRS Congress

Reviva to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Reviva to Participate in the 2025 BIO CEO & Investor Conference

Reviva to Participate in the Lytham Partners 2025 Investor Healthcare Summit

RVPH: Preliminary OLE Readout

Applied Therapeutics Appoints John H. Johnson as Executive Chairman

Reviva Pharmaceuticals Strengthens Financial Position with Offering

Top Midday Decliners

Reviva Announces Proposed Public Offering

Reviva Announces Positive Preliminary Topline Data for the Long-Term Open Label Extension Portion of the Phase 3 RECOVER Study Evaluating Brilaroxazine in Schizophrenia

RVPH: Year-End OLE Update

Reviva Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Reviva Announces Enrollment Update for Open Label Extension Study Evaluating Brilaroxazine in Schizophrenia

Reviva to Present Positive Speech Latency Data for Brilaroxazine in Schizophrenia From the Phase 3 RECOVER Trial at the CNS Summit 2024

Reviva to Participate in the UBS Global Healthcare Conference

Reviva to Participate in the 2024 Maxim Healthcare Virtual Summit

Performance Overview